Tine Bondo
Abstract
Master Student: Tine BondoSpecialisation: Internal Medicine
Project: Evidence based medicine regarding SDMA as an early biomarker of chronic kidney disease in cats”
Background:
CKD is a commonly recognized disease in cats, but diagnosing it early is challenging. SDMA concentration has been investigated and found to be highly correlated with GFR in humans. It would be added value to practitioners in veterinary medicine to know, whether SDMA can help diagnosing cats with CKD earlier. A systematic review was performed.
Objective:
The objective of this study was to look for evidence based medicine concerning the use of symmetric dimethylarginine (SDMA) as an early biomarker of Chronic Kidney Disease in cats. 0‐Hypothesis: “No difference is seen in time of diagnosis of Chronic Kidney Disease (CKD) in cats when Symmetric Dimethylarginine (SDMA) is used as biomarker compared to creatinine”
Methods:
A review was performed searching AGRICOLA, AGRIS, CAB Abstracts, Embase, Ovid MEDLINE
Conclusions and clinical importance:
SDMA seems to be a helpful parameter when assessing kidney function in cats with suspicion of early chronic kidney disease (CKD) (or other kidney related disease) and the 0‐hypothesis: “No difference is seen in time of diagnosis of Chronic Kidney Disease (CKD) in cats, when SDMA is used as biomarker compared to creatinine” can therefore not be accepted. Based on the very limited amount of studies evidence based use of SDMA as an early indicator of CKD in cats is a challenge. Given the facts that diagnosis of CKD can be challenging, SDMA can be included as a part of routine examinations in cats suspected to have CKD contributing to the diagnosis as a part of the puzzle, but acknowledging that so far it is based on a limited amount of studies and hence limited evidence in cats.
